Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
Steven I. Sherman, Lori J. Wirth, Jean‐Pierre Droz et al. · New England Journal of Medicine · 2008
BACKGROUND: The expression of vascular endothelial growth factor (VEGF) is characteristic of differentiated thyroid cancer and is associated with aggressive tumor behavior and a poor clinical outcome. Motesanib diphosphate (AMG 706) is a novel oral inhibitor of VEGF receptors, platelet-derived growth-factor receptor, and KIT. METHODS: In an open-label, single-group, phase 2 study, we treated 93 patients who had progressive, locally advanced or metastatic, radioiodine-resistant differentiated thyroid cancer with 125 mg of motesanib diphosphate, administered orally once daily. The primary end point was an objective response as assessed by an independent radiographic review. Additional end points included the duration of the response, progression-free survival, safety, and changes in serum thyroglobulin concentration. RESULTS: Of the 93 patients, 57 (61%) had papillary thyroid carcinoma. The objective response rate was 14%. Stable disease was achieved in 67% of the patients, and stable disease was maintained for 24 weeks or longer in 35%; 8% had progressive disease as the best response. The Kaplan-Meier estimate of the median duration of the response was 32 weeks (the lower limit of the 95% confidence interval [CI] was 24; the upper limit could not be estimated because of an insufficient number of events); the estimate of median progression-free survival was 40 weeks (95% CI, 32 to 50). Among the 75 patients in whom thyroglobulin analysis was performed, 81% had decreased serum thyroglobulin concentrations during treatment, as compared with baseline levels. The most common treatment-related adverse events were diarrhea (in 59% of the patients), hypertension (56%), fatigue (46%), and weight loss (40%). CONCLUSIONS: Motesanib diphosphate can induce partial responses in patients with advanced or metastatic differentiated thyroid cancer that is progressive. (ClinicalTrials.gov number, NCT00121628.)
Cited by 473 works. doi:10.1056/nejmoa075853 Open-access PDF
Authors
- Steven I. Sherman
- Lori J. Wirth
- Jean‐Pierre Droz
- Michael Hofmann
- Lars Bastholt
- Renato G. Martins
- Lisa Francesca Licitra
- Michael J. Eschenberg
- Yu‐Nien Sun
- Todd Juan
- Daniel E. Stepan
- Martin Jean Schlumberger
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce
- Papillary and Follicular Thyroid Carcinoma
- A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995
- Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy
- Thyroid carcinoma
- Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
- Phase II Trial of Sorafenib in Advanced Thyroid Cancer
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
- Chemotherapy of Thyroid Cancer with Adriamycin